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EDITOR’S CORRESPONDENCE
COMMENTS AND OPINIONS
Designing Appropriate Clinical Trials
to Assess ACEI Use and Cognitive Decline
in Older Adults With Hypertension
S ink et al
1 report that exposure to angiotensin-
converting enzyme inhibitors (ACEIs) is not as-
sociated with dementia risk or cognitive decline
in older hypertensive adults compared with other anti-
hypertensive drugs. Centrally active ACEIs, ie, those that
cross the blood-brain barrier (BBB) (animal data), re-
duced cognitive decline, whereas noncentrally acting
ACEIs (BBB impermeable) were associated with greater
risk of incident dementia and disability in instrumental
activities of daily living.1 These effects were indepen-
dent of blood pressure regulation and prompted a call
for a randomized clinical trial of centrally active ACEIs
in the prevention of cognitive decline and dementia.1
Controversies remain. Angiotensin-converting en-
zyme inhibitors modulate progression of amnestic mild
cognitive impairment.2 With the analysis limited to di-
hydropyridines or diuretics, significant benefits on de-
mentia are suggested.3 The only study in older hyper-
tensive patients to show a significant effect was
nitrendipine based.3 A recent study found that any an-
tihypertensive medication, but particularly potassium-
sparing diuretics, was associatedwith lower risks for Alz-
heimer disease (AD).3 The most recent study findings in
very elderly people, involving perindopril and indap-
amide, were negative.4
In their discussion, Sink et al1 fail to make the point
that the intervention in the Perindopril ProtectionAgainst
Recurrent Stroke Study (PROGRESS) was perindopril
based, ie, treatment was perindopril plus indapamide (re-
ceived by 58% of subjects). Therefore, an effect could not
be concluded to be on the basis of perindopril use alone.3
The design of hypertension studies was not powered pri-
marily on the outcome of cognition or dementia. The fol-
lowing unresolved issues remain: Does treatment of hy-
pertension inmiddle age reduce cognitive decline and/or
dementia in late-life? Does treatment of hypertension in
older adults reduce cognitive decline and the risk of de-
mentia? Are any benefits associated with a specific regi-
men? Future studies must have cognition and dementia
as a primary outcome. Given that the study population
is relatively cognitively normal, the optimal study de-
sign should include specific tests of attention, episodic
memory, and other measures of executive function.5 It
may be possible to examine the effects of individual agents
within those designs but the numbers required are likely
to be very large. The important issue of equivalent blood
pressure control in comparative groups compared with
the treatment regimen is problematic but achievable.With
the current focus on management of overall cardiovas-
cular risk, studies must factor in the use of antiplatelet,
lipid-lowering, and other interventions. Perhaps the pri-
ority area for study, given the increasing awareness of the
interface between AD and cardiovascular risk factors, is
the role of modulation of cardiovascular risk on disease
progress in patients with established AD.
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W e read with interest the article by Sink andcolleagues1 describing an association be-tween the use of centrally active ACEIs that
can cross the BBB and a reduction in cognitive decline
in a large, well-characterized cohort of treated older adults
with hypertension. Using computerized information on
patients in our university hospital, we also found that the
long-term use of centrally active ACEIs (captopril or per-
indopril) is associated with a lower risk of incident de-
mentia compared with other antihypertension drugs in
elderly hypertensive patients.2 Furthermore, we found
that the centrally active ACEIs significantly reduce the
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